UPDATE: Leerink Swann Starts Celldex Therapeutics (CLDX) at Outperform

March 6, 2013 7:18 AM EST Send to a Friend
Get Alerts CLDX Hot Sheet
Price: $15.41 --0%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 22 | Down: 26 | New: 13
Trade CLDX Now!
Join SI Premium – FREE
(Updated - March 6, 2013 7:23 AM EST)

Leerink Swann initiated coverage on Celldex Therapeutics (NASDAQ: CLDX) with an Outperform rating and a price target of $18.

Analyst Howard Liang said, "With 6 wholly owned clinical-stage biologics assets providing multiple shots on goal, the breadth of its portfolio is rare among small and mid-cap biotech companies."

For an analyst ratings summary and ratings history on Celldex Therapeutics click here. For more ratings news on Celldex Therapeutics click here.

Shares of Celldex Therapeutics closed at $10.71 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Add Your Comment